Sema4 (NASDAQ: SMFR – Get an assessment) saw its target price lowered by Compass Point to $5.00 in a report on Monday, Stock Target Advisor reports. The brokerage currently has a na rating on the stock.
A number of other research analysts have also recently commented on the company. Zacks Investment Research downgraded Sema4 from a hold rating to a sell rating in a Tuesday, May 10 report. Cowen reduced its target price on Sema4 from $13.00 to $5.00 in a report released on Monday. Finally, BTIG Research reaffirmed a Buy rating and set a target price of $8.00 on Sema4 shares in a Friday, January 21 report. One analyst has rated the stock with a sell rating and four have assigned the company a buy rating. According to data from MarketBeat, the stock has a consensus buy rating and a consensus target price of $8.60.
Shares of SMFR opened at $2.00 on Monday. Sema4 has a 1-year low of $1.49 and a 1-year high of $15.21. The company has a debt ratio of 0.08, a current ratio of 4.77 and a quick ratio of 4.44. The stock has a 50-day moving average price of $2.58 and a 200-day moving average price of $4.06.
Sema4 (NASDAQ:SMFR – Get Rating) last released its quarterly results on Monday, March 14. The company reported ($0.17) EPS for the quarter, beating analyst consensus estimates of ($0.22) by $0.05. The company posted revenue of $57.80 million in the quarter, compared to $50.90 million expected by analysts. On average, equity research analysts expect Sema4 to post -0.8 earnings per share for the current year.
In related news, Chief Financial Officer Isaac Ro sold 19,515 shares of the company in a trade that took place on Tuesday, May 10. The stock was sold at an average price of $2.46, for a total value of $48,006.90. Following the sale, the CFO now owns 201,786 shares of the company, valued at approximately $496,393.56. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Additionally, director Keith A. Meister purchased 11,437,500 shares of the company in a transaction that took place on Friday, April 29. The shares were purchased at an average cost of $4.00 per share, for a total transaction of $45,750,000.00. Following the acquisition, the administrator now owns 26,931,250 shares of the company, valued at approximately $107,725,000. Disclosure of this purchase can be found here. In the past three months, insiders have sold 33,099 shares of the company worth $79,156.
Institutional investors and hedge funds have recently been buying and selling stocks. Morgan Stanley acquired a new stake in Sema4 in Q3 valued at approximately $27,688,000. Viking Global Investors LP acquired a new position in shares of Sema4 during Q3 at a value of $22,770,000. Bleichroeder LP acquired a new position in shares of Sema4 during Q3 worth $759,000. SB Management Ltd acquired a new position in shares of Sema4 during Q3 with a value of $68,473,000. Finally, Oxbow Advisors LLC acquired a new position in shares of Sema4 during Q3 worth $231,000.
About Sema4 (Get a rating)
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that improves the diagnosis, treatment and prevention of disease through data. The Company provides Centrellis, an AI-powered health intelligence platform that delivers comprehensive insights to biopharma to accelerate the lifecycle of drug discovery, development and commercialization, as well as analytics for actionable insights, preclinical and clinical trial support, and advanced analytics. sequencing service.
Get news and reviews for Sema4 Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Sema4 and related companies with MarketBeat.com’s free daily email newsletter.